203 related articles for article (PubMed ID: 25582437)
1. Correlation between CT perfusion and clinico-pathological features in prostate cancer: a prospective study.
Łuczyńska E; Heinze-Paluchowska S; Blecharz P; Jereczek-Fossa B; Petralia G; Bellomi M; Stelmach A
Med Sci Monit; 2015 Jan; 21():153-62. PubMed ID: 25582437
[TBL] [Abstract][Full Text] [Related]
2. Assessment of prostate cancer with dynamic contrast-enhanced computed tomography using an en bloc approach.
Huellner MW; Pauli C; Mattei A; Ross S; Diebold J; Vosbeck J; Allgayer B; Strobel K; Veit-Haibach P
Invest Radiol; 2014 Sep; 49(9):571-8. PubMed ID: 24710202
[TBL] [Abstract][Full Text] [Related]
3. Integrated CT-perfusion shows no meaningful correlation with PSA and presurgical Gleason score in patients with early prostate cancer.
Huellner MW; Mattei A; Ross S; Butea-Bocu M; Vosbeck J; Pauli C; Diebold J; Seifert B; Strobel K; Veit-Haibach P
Clin Imaging; 2014; 38(6):850-7. PubMed ID: 25168905
[TBL] [Abstract][Full Text] [Related]
4. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
5. Perfusion CT is a valuable diagnostic method for prostate cancer: a prospective study of 94 patients.
Luczynska E; Blecharz P; Dyczek S; Stelmach A; Petralia G; Bellomi M; Jereczek-Fossa BA; Jakubowicz J
Ecancermedicalscience; 2014; 8():476. PubMed ID: 25435904
[TBL] [Abstract][Full Text] [Related]
6. Correlation of the primary Gleason pattern on prostate needle biopsy with clinico-pathological factors in Gleason 7 tumors.
Grober ED; Tsihlias J; Jewett MA; Sweet JM; Evans AJ; Trachtenberg J; Robinette M; Nam RK
Can J Urol; 2004 Feb; 11(1):2157-62. PubMed ID: 15003158
[TBL] [Abstract][Full Text] [Related]
7. A solitary positive prostate cancer biopsy does not predict a unilateral lesion in radical prostatectomy specimens.
Koie T; Mitsuzuka K; Narita S; Yoneyama T; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C
Scand J Urol; 2015 Apr; 49(2):103-7. PubMed ID: 25165894
[TBL] [Abstract][Full Text] [Related]
8. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
9. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
[TBL] [Abstract][Full Text] [Related]
10. Preoperative Serum Prostate-Specific Antigen Levels Vary According to the Topographical Distribution of Prostate Cancer in Prostatectomy Specimens.
Eminaga O; Hinkelammert R; Abbas M; Wötzel F; Eltze E; Bettendorf O; Boegemann M; Semjonow A
Urology; 2015 Oct; 86(4):798-804. PubMed ID: 26255036
[TBL] [Abstract][Full Text] [Related]
11. The presence of positive surgical margins in patients with organ-confined prostate cancer results in biochemical recurrence at a similar rate to that in patients with extracapsular extension and PSA ≤ 10 ng/ml.
Eminaga O; Hinkelammert R; Titze U; Abbas M; Eltze E; Bettendorf O; Semjonow A
Urol Oncol; 2014 Jan; 32(1):32.e17-25. PubMed ID: 23434425
[TBL] [Abstract][Full Text] [Related]
12. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool.
Briganti A; Passoni N; Ferrari M; Capitanio U; Suardi N; Gallina A; Da Pozzo LF; Picchio M; Di Girolamo V; Salonia A; Gianolli L; Messa C; Rigatti P; Montorsi F
Eur Urol; 2010 Apr; 57(4):551-8. PubMed ID: 20034730
[TBL] [Abstract][Full Text] [Related]
13. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
14. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
Castellucci P; Ceci F; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Pettinato C; Celli M; Lodi F; Fanti S
J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
[TBL] [Abstract][Full Text] [Related]
15. Outcome prediction after surgery and chemoradiation of squamous cell carcinoma in the oral cavity, oropharynx, and hypopharynx: use of baseline perfusion CT microcirculatory parameters vs. tumor volume.
Bisdas S; Nguyen SA; Anand SK; Glavina G; Day T; Rumboldt Z
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1313-8. PubMed ID: 18963541
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
Raj GV; Partin AW; Polascik TJ
Cancer; 2002 Feb; 94(4):987-96. PubMed ID: 11920467
[TBL] [Abstract][Full Text] [Related]
17. Role of CT perfusion imaging in patients with variously differentiated gastric adenocarcinoma.
Sun ZQ; Cheng XF; Ge YX; Chen L; Yue JG; Jin LF; Xie ZH; Zhang HD; Xuan YH
J Xray Sci Technol; 2015; 23(6):737-44. PubMed ID: 26756409
[TBL] [Abstract][Full Text] [Related]
18. Gleason inflation 1998-2011: a registry study of 97,168 men.
Danneman D; Drevin L; Robinson D; Stattin P; Egevad L
BJU Int; 2015 Feb; 115(2):248-55. PubMed ID: 24552193
[TBL] [Abstract][Full Text] [Related]
19. Pathological features of Gleason score 6 prostate cancers in the low and intermediate range of prostate-specific antigen level: is there a difference?
Pelzer AE; Colleselli D; Bektic J; Steiner E; Ramoner R; Mitterberger M; Schwentner C; Schaefer G; Ongarello S; Bartsch G; Horninger W
BJU Int; 2008 Apr; 101(7):822-5. PubMed ID: 18261154
[TBL] [Abstract][Full Text] [Related]
20. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
